PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 15, 2026npj DementiaOpen Access

XPro1595 in early Alzheimer’s disease with inflammation: results from the phase 2 MINDFuL trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JJJudith JaegerKSKim A. StaatsSBSarah Barnum

Discussion

Loading...

Member takes

Overview

Randomized trial tests XPro1595 for cognitive improvement in early Alzheimer's patients, suggesting therapeutic potential.

Key Points

  • This research aims to assess the efficacy of XPro1595 in improving cognitive function in patients with early Alzheimer's disease and inflammation.
  • Phase 2, multicenter, randomized, double-blind, placebo-controlled trial with 200 participants (n = 200).
  • Participants received XPro1595 (1.0 mg/kg) or placebo for 24 weeks, focusing on cognitive outcomes.
  • The analysis included a biomarker-enriched population with amyloid positivity and at least two inflammatory markers.
  • No difference in EMACC scores across the mITT population (p = 0.672).
  • In the ADi population (n = 100), XPro1595 showed cognitive and neuropsychiatric benefits (Cohen’s d for EMACC = 0.27).
  • XPro1595 reduced plasma pTau217 (d = -0.18) and GFAP (d = -0.19), with larger effects in those with higher drug exposure.

Cite This Study

Jaeger et al. (2026) studied this question.

synapsesocial.com/papers/6a06b928e7dec685947abb6ahttps://doi.org/10.1038/s44400-026-00091-x
View Full Paper
Ask AI
Bookmark
Share